Cargando…
Evaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer’s Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant
BACKGROUND: Many patients with Alzheimer’s disease (AD) display circadian rhythm and sleep-wake disturbances. However, few mouse AD models exhibit these disturbances. Lemborexant, a dual orexin receptor antagonist, is under development for treating circadian rhythm disorders in dementia. OBJECTIVE:...
Autores principales: | Beuckmann, Carsten T., Suzuki, Hiroyuki, Musiek, Erik S., Ueno, Takashi, Sato, Toshitaka, Bando, Masahiro, Osada, Yoshihide, Moline, Margaret |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293654/ https://www.ncbi.nlm.nih.gov/pubmed/33843668 http://dx.doi.org/10.3233/JAD-201054 |
Ejemplares similares
-
Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation
por: Beuckmann, Carsten Theodor, et al.
Publicado: (2019) -
Hypocretin (orexin) regulation of sleep-to-wake transitions
por: de Lecea, Luis, et al.
Publicado: (2014) -
The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
por: Moline, Margaret, et al.
Publicado: (2023) -
THE REGULATION OF SLEEP AND WAKEFULNESS BY THE HYPOTHALAMIC NEUROPEPTIDE OREXIN/HYPOCRETIN
por: INUTSUKA, AYUMU, et al.
Publicado: (2013) -
Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)